Pharmacology & Pharmacy Journals
药理学与药学期刊合辑
探索领域内各类期刊，发现合你心意的发文平台Taylor & Francis 旗下30余本药学期刊分享研发进展、最新发现。其中，专家见解（Expert Opinion）系列涵盖了药物研发的各个阶段，涉及生物治疗、药物发现、药物输送、药物代谢、药物安全、药物治疗、新兴药物等多个领域。
Expert Opinion on Drug Delivery
Impact Factor: 5.0 (2023)
Q1
Providing comprehensive coverage of drug delivery research, including delivery technologies, vehicles, formulations and devices, the delivery of specific drug and therapeutic classes, modes of entry into the body, and applications in diseases. This journal offers accelerated publication.
Expert Opinion on Therapeutic Patents
Impact Factor: 5.4 (2023)
Q1
Publishing reviews and patent evaluations covering recent patent claims/applications on compounds with therapeutic potential, including biotherapeutics and small-molecule agents with specific molecular targets, and patenting trends in a therapeutic area. This journal offers accelerated publication.
Expert Opinion on Drug Discovery
Impact Factor: 6.0 (2023)
Q1
A MEDLINE-indexed, peer-reviewed, international journal publishing review articles on novel technologies involved in the drug discovery process, leading to new leads and reduced attrition rates. It offers accelerated publication.
Expert Opinion on Investigational Drugs
Impact Factor: 4.9 (2023)
Q1
A MEDLINE-indexed journal primarily publishing Reviews, Original Research, Editorials and Perspectives. The emphasis is on drugs or drug classes in early stage clinical trials and preclinical development and their potential impact on future treatment strategies. This journal offers accelerated publication
Drug Delivery
6.5 (2023)
Q1
Publishes open access research on oral, pulmonary, nasal, parental and transdermal drug delivery systems and conjugates, and drug entry and targeting.
Drug Metabolism Reviews
3.4 (2023)
Q2
An international journal that publishes reviews on drug metabolism research covering environmentally toxic chemicals, absorption, metabolism, and excretion.
Expert Opinion on Therapeutic Targets
4.6 (2023)
Q1
A MEDLINE-indexed journal covering novel molecular disease targets while providing expert opinion on their scope for future drug development and the impact on drug discovery. Content evaluates molecules, signaling pathways, receptors, and other therapeutic targets. It offers accelerated publication
Drug Design, Development and Therapy
4.7 (2023)
Q1
Publishes open access research on targeted drug design, including pharmacokinetics, molecular studies, biological compounds, toxicology, and gene therapy.
Journal of Drug Targeting
4.3 (2023)
Q1
Medline-indexed research on targeting and delivery of molecular and macromolecular drugs, carrier systems, and diagnostic, in vivo and in vitro applications.
It
offers accelerated publication.
Expert Review of Clinical Pharmacology
3.6 (2023)
Q2
Medline-indexed clinical pharmacology research on drug evaluation, safety, toxicity, tolerability, efficacy, genomics, adverse reactions and pharmacoeconomics. This journal offers accelerated publication.
Journal of Liposome Research
3.6 (2023)
Q2
Accepts articles on liposomes, lipid-based delivery systems, lipid biology, lipid technology, synthetic and physical lipid chemistry, biomembranes and vaccines.
Expert Opinion on Drug Metabolism & Toxicology
3.9 (2023)
Q1
A forum for the commentary and analysis of current and emerging research approaches in the ADME-Tox arena, as well as metabolic, pharmacokinetic and toxicological issues relating to specific drugs, drug-drug interactions and drug classes. This journal offers accelerated publication.
Journal of Pharmaceutical Policy and Practice
3.3 (2023)
Q1
Publishes research on all aspects of pharmacy, including clinical, social, administration and economics. The Editor-in-Chief is Professor Zaheer Babar.
Biologics: Targets and Therapy
5.3 (2023)
Q1
Publishes open access research on biologic agents, including gene and cell therapy, antibodies, blood components, hormones, and cytokines and growth factors.
Infection and Drug Resistance
2.9 (2023)
Q2
Publishes open access research on anti-infectives, epidemiology, vaccine development and the pathogenesis, etiology and diagnosis of infectious disease.
Drug Development and Industrial Pharmacy
2.4 (2023)
Publishes pharmaceutical research on formulations, preclinical development, drug delivery, processing and analytical technology and regulatory science.
It
offers accelerated publication.
Expert Review of Proteomics
3.8 (2023)
Q1
Expert reviews, original research and commentary on proteomics, protein and biological assays, interaction maps, and data archives, and implications for drug discovery and clinical practice.
Expert Opinion on Pharmacotherapy
2.5 (2023)
A MEDLINE-indexed journal publishing reviews, drug evaluations, original research and editorials on chemical/synthetic pharmacotherapy from late phase III development to 5 years post launch across all therapy areas. This journal offers accelerated publication.
Integrated Pharmacy Research and Practice
2.1 (2023)
Publishes open access research on pharmacy practice, focusing on community, hospital and industrial pharmacy, pharmaceutical science, and medicolegal issues.
Clinical Pharmacology: Advances and Applications
3.1 (2023)
Q2
Publishes clinical trials, with a focus on early trials, including detailed pharmacological data, predicted applications, side effects, and safety and efficacy.
Journal Of Pain & Palliative Care Pharmacotherapy
0.9 (2023)
Addresses advances in acute, chronic and end-of-life symptom management in pharmacotherapy and its ethics, efficacy, safety and availability.
Journal of Microencapsulation
3.0 (2023)
Q2
Medline-indexed research on the preparation, properties and uses of encapsulated small and nano particles in medicine, agriculture, photography and industry.
Expert Opinion on Emerging Drugs
2.7 (2023)
Q2
A MEDLINE-indexed journal publishing structured reviews on Phase II and Phase III drugs/drug classes emerging onto the market across all therapy areas, providing expert opinion on their potential impact on the current management of specific diseases. It offers accelerated publication.
Pharmaceutical Development and Technology
2.6 (2023)
Q2
Publishes research on the design, development, manufacture, and evaluation of conventional and novel drug delivery systems.
It
offers accelerated publication.
Expert Opinion on Drug Safety
3.0 (2023)
Q2
A MEDLINE-indexed journal publishing reviews on all aspects of drug safety, adverse events, and pharmacovigilance, as well as original research on the clinical implications of drug treatment safety issues. This journal offers accelerated publication.
Expert Review of Pharmacoeconomics & Outcomes Research
1.8 (2023)
Publishes double-blinded articles on cost-benefit and pharmacoeconomic issues in clinical drug use, therapeutic approaches, and evidence-based medicine.
Pharmacogenomics and Personalized Medicine
1.8 (2023)
Publishes open access research on targeted drug identification, discovery and delivery, genetic variability in drug toxicity and efficacy, personalized medicine.
Expert Opinion on Orphan Drugs
0.8 (2023)
Covering all aspects of research and development on rare diseases and orphan drugs. Topics include pharmacogenomics and screening, prevalence and epidemiology, drug development, clinical trials, regulatory issues, post-marketing safety, and treatment outcomes. It offers accelerated publication.
了解更多药理学和药学及其他各学科高水平国际期刊，欢迎访问 Taylor & Francis Group 旗下学术期刊网站， 欢迎相关学科研究人员向您青睐的期刊投稿。
期刊网站：www.tandfonline.com
医学与健康领域部分期刊已开放加速出版服务！从投稿到发表最快仅需3周！
加速出版：https://taylorandfrancis.com/partnership/commercial/accelerated-publication/
Taylor & Francis 编辑润色服务
在准备向期刊提交稿件的时候，您需要协助吗？ Taylor & Francis 编辑润色服务提供包括英语语言编辑、科学润色、翻译加编辑、稿件格式调整、相似度检查以及技术审核等，让您将时间集中在研究上。
为期刊、图书作者提供的实用指南
在您准备撰写一篇国际学术论文时，一个为您提供必要指导和资源实用网站可以为您解答许多疑问！从选刊、写作、投稿、同行评审、出版等各个方面给予详细的指导，写作投稿前的必看网站！
拥抱开放科学
开放获取对于作者、读者而言极具价值，开放科学让研究在更广泛的维度得到参考和使用，提升研究可见度和影响力，造福社会。您是否考虑发表开放获取文章？点击了解开放获取出版更多信息
联系我们
Taylor & Francis Group拥有220多年的历史，是全球领先的学术出版集团，业务包括学术期刊、图书、电子书、教科书和参考书。以高质量的学术内容和服务水平，每年出版期刊2700余种，图书14万余册。旗下包括Routledge, CRC Press, Taylor & Francis等品牌，实现全学科均衡覆盖。我们整合数据、资源和技术优势，愿为中国研究人员和中国开放科学的发展提升，贡献更多的智慧和力量。